Get the Stockscreener App
7.51
6.52%
0.46
After Hours:
7.54
0.03
+0.40%
Neuraxis Inc stock is traded at $7.51, with a volume of 181.15K.
It is up +6.52% in the last 24 hours and up +42.23% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$7.05
Open:
$7
24h Volume:
181.15K
Relative Volume:
0.46
Market Cap:
$84.02M
Revenue:
$3.57M
Net Income/Loss:
$-7.80M
P/E Ratio:
-7.7399
EPS:
-0.9703
Net Cash Flow:
$-6.56M
1W Performance:
+7.44%
1M Performance:
+42.23%
6M Performance:
+173.09%
1Y Performance:
+242.92%
1-Day Range:
$6.91
$7.80
1-Week Range:
$6.04
$7.97
52-Week Range:
$1.33
$7.97
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.51 | 78.87M | 3.57M | -7.80M | -6.56M | -0.9703 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Neuraxis Inc Stock (NRXS) Latest News
Treasury Yields: Should I trade or invest in NeurAxis Inc2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth - TradingView
NeurAxis Shares Rise After Q4 Results Driven by Robust Revenue Expansion - Bitget
If You Invested $1,000 in Neuraxis Inc (NRXS) - Stock Titan
Craig Hallum Increases NeurAxis (NASDAQ:NRXS) Price Target to $13.00 - Defense World
Dip Buying: Can NeurAxis Inc outperform under higher oil prices2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Gainers Report: Can NeurAxis Inc expand its profit marginsEarnings Beat & AI Powered Market Entry Ideas - baoquankhu1.vn
Neuraxis, Inc.: Fundamental Analysis and Financial Ratings | NRXS | US64134X2018 - marketscreener.com
NeurAxis (NASDAQ:NRXS) Given New $13.00 Price Target at Craig Hallum - MarketBeat
NeurAxis Earnings Call: Reimbursement Wins Drive Next Phase - TipRanks
Earnings call transcript: NeurAxis Q4 2025 sees revenue growth, stock dips - Investing.com Australia
NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NeurAxis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
NRXS: FY2025 revenue rose 33% to $3.6M, with improved net loss and expanded market access - TradingView
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Neuraxis 10-K: $3.57M Revenue, $(7.80)M Net Loss - TradingView
NeurAxis says its pain-treatment device now reaches 100M insured lives - Stock Titan
Neuraxis (NRXS) expands IB-Stim GI neuromodulation, RED constipation device and IP moat - Stock Titan
Levels Update: Should I trade or invest in NeurAxis Inc2026 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC) - The Globe and Mail
Aug Ideas: What is the implied volatility of NeurAxis Inc2026 Fed Impact & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
NeurAxis, Inc. Hits New 52-Week High of $7.46, Up 141.44% - Markets Mojo
Breakout Zone: Is NeurAxis Inc impacted by rising ratesTrade Exit Report & Stock Portfolio Risk Control - baoquankhu1.vn
NeurAxis, Inc. Hits New 52-Week High at USD 7.34 - Markets Mojo
Neuraxis price target raised to $8 from $7 at Craig-Hallum - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026 - Sahm
Medical tech firm NeurAxis schedules March 19 call on 2025 results - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
NeurAxis (NASDAQ:NRXS) Shares Up 0.7%Still a Buy? - MarketBeat
NeurAxis, Inc. Hits New 52-Week High of $6.35, Up 98.97% - Markets Mojo
Volume Recap: Can TTWO expand its profit marginsJuly 2025 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
How FlexShares iBoxx 3 Year Target stock trades in high volatilityMarket Activity Summary & Reliable Price Breakout Signals - Naître et grandir
Update Recap: Should you avoid OSCR stock right now2025 Macro Impact & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Highlights: Can NeurAxis Inc stock outperform in a bear marketJuly 2025 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Chronic Idiopathic Constipation Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland - Barchart.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
00152 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NeurAxis, Inc. Hits New 52-Week High of $6.30, Up 115.75% - Markets Mojo
S32 Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BPCF Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neuraxis (NRXS) awards 47,569 RSUs to senior executive Miranda - Stock Titan
P 500Share Buyback & Expert Approved Trade Ideas - mfd.ru
NRXS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Director at Neuraxis (NRXS) receives 21,598-share equity grant as compensation - Stock Titan
Neuraxis (NRXS) CEO granted 94,173 RSUs in three-year vesting award - Stock Titan
Director at Neuraxis (NRXS) receives 21,598-share stock grant as compensation - Stock Titan
SMN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LINK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Cap:
|
Volume (24h):